MoneyWorks4Me

Suven Life Sciences informs about press release

16 Jun 2026 Evaluate
Suven Life Sciences has informed that it enclosed News Release of the company titled ‘Suven Life Sciences announces successful completion and topline results of First-in-Human (FIH) Phase-1 clinical study of SUVN-I6107, a Muscarinic M1 Positive Allosteric Modulator (M1-PAM) and its advancement into Phase-2 clinical development’.

The above information is a part of company’s filings submitted to BSE. 

Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1145.25
Cipla 1359.75
Lupin 2047.20
Zydus Lifesciences 1105.00
View more..